Bone marrow-derived mesenchymal stem cells (BMSC) modulate inflammatory/immune responses and promote motor functional recovery after spinal cord injury (SCI). However, the effects of BMSC transplantation on central neuropathic pain and neuronal hyperexcitability after SCI remain elusive. This is of importance because BMSC-based therapies have been proposed for clinical treatment. We investigated the effects of BMSC transplantation on pain hypersensitivity in green fluorescent protein (GFP)-positive bone marrow-chimeric mice subjected to a contusion SCI, and the mechanisms of such effects. BMSC transplantation at day 3 post-SCI improved motor function and relieved SCI-induced hypersensitivities to mechanical and thermal stimulation. The pain improvements were mediated by suppression of protein kinase C-c and phosphocyclic AMP response element binding protein expression in dorsal horn neurons. BMSC transplants significantly reduced levels of p-p38 mitogen-activated protein kinase and extracellular signal-regulated kinase (p-ERK1/2) in both hematogenous macrophages and resident microglia and significantly reduced the infiltration of CD11b and GFP double-positive hematogenous macrophages without decreasing the CD11b-positive and GFP-negative activated spinal-microglia population. BMSC transplants prevented hematogenous macrophages recruitment by restoration of the blood-spinal cord barrier (BSCB), which was associated with decreased levels of (a) inflammatory cytokines (tumor necrosis factor-a, interleukin-6); (b) mediators of early secondary vascular pathogenesis (matrix metallopeptidase 9); (c) macrophage recruiting factors (CCL2, CCL5, and CXCL10), but increased levels of a microglial stimulating factor (granulocyte-macrophage colony-stimulating factor). These findings support the use of BMSC transplants for SCI treatment. Furthermore, they suggest that BMSC reduce neuropathic pain through a variety of related mechanisms that include neuronal sparing and restoration of the disturbed BSCB, mediated through modulation of the activity of spinal-resident microglia and the activity and recruitment of hematogenous macrophages.
INTRODUCTION
Spinal cord injury (SCI) not only results in loss of normal sensation, but often debilitating neuropathic pain. Up to 80% of patients with SCI develop chronic neuropathic pain, which can be localized below, girdling, or above the level of the SCI lesion [1] [2] [3] [4] . Beneficial effects of cell transplantation therapy in sensory recovery and reduced pain after SCI have been reported [5, 6] ; however, other studies described harmful effects of cell transplants [7, 8] . Research has shown that autologous bone marrow-derived mesenchymal stem cell (BMSC) transplants increase sensory function after contusion SCI, but the effects of BMSC on SCI-induced chronic neuropathic pain remain contentious [9] [10] [11] [12] . This is problematic because BMSC transplants for SCI treatments are being developed for clinical applications [13] [14] [15] .
Neuropathic pain following SCI is associated with a number of molecular and cellular events. SCI results in a marked increase in extracellular concentrations of glutamate followed by activation of excitatory amino acid receptors and ion channels [16] with subsequent activation of intracellular downstream pathways that result in altered gene expression. These events are sufficient to produce persistent neuronal hyperexcitability of spinal dorsal horn neurons or central neuropathic pain [17] . The mechanism of neuropathic pain after SCI involves the activation of members of the mitogen-activated protein kinase (MAPK) family, in particular, p38 MAPK, extracellular signal-regulated kinase (ERK) including ERK1/2, and c-Jun Nterminal kinase (JNK) [18] . Experimental models of peripheral neuropathic pain have also highlighted the roles of MAPK in neuronal hyperexcitability and demonstrated the selective expression of MAPK in activated microglia present in the spinal cord dorsal horn [19, 20] . Following thoracic SCI, both p38 MAPK and ERK are activated in spinal microglia, which contributes to neuronal hyperexcitability and central neuropathic pain [17, [21] [22] [23] . Furthermore, inhibition of microglial activation by minocycline (an anti-inflammatory drug) was reported to reduce SCI-induced pain below the injury site by attenuating p38 MAPK and ERK activation in microglia [23, 24] .
Although activated microglia are thought to contribute to neuropathic pain symptoms through their release of modulators of neuronal excitability [25] , these data derive largely from analyses of resident cells at sites remote and caudal to thoracic lesions [22, 26, 27] . However, following thoracic SCI the blood-spinal cord barrier (BSCB) is often disrupted and an influx of blood-borne inflammatory and other immune cells contribute to an intensive inflammatory response localized around the injured site [28] . Infiltrating macrophages have both detrimental [29, 30] and beneficial roles [31, 32] in spinal repair, although the net effect of their activity is unclear. In addition, it is not well-known how activated resident microglia and macrophages of different origins contribute to post-SCI dorsal horn hyperexcitability and central neuropathic pain, particularly at the level of the lesion. One reason for the difficulty in differentiating microglia from infiltrating monocytes/ macrophages relates to their morphological and phenotypic similarities [33] . However, in response to peripheral nerve injury, there is increasing evidence that infiltration of peripheral immune cells, including macrophages, into the spinal cord contributes to the pathogenesis of neuropathic pain [34, 35] . Understanding the contribution of each cell type, that is, of inflammatory cells of hematogenous monocytic lineage versus resident microglia to SCI-induced neuropathic pain is important to direct the search for novel therapies, especially involving BMSC transplants as these are known to influence macrophage activity.
In this study, we investigated the effects of BMSC transplantation on post-SCI chronic neuropathic pain. Specifically, we focused on the effects of BMSC transplants on microglia and macrophages and MAPK signalling at the level of the lesion. Furthermore, we used chimeric mice wherein the bone marrow contained hematogenous cells that expressed green fluorescent protein (GFP). This was to determine the differential effects of transplanted BMSC on spinal-resident microglia and bone marrow-derived macrophages.
MATERIALS AND METHODS

Experimental Animals
All experiments followed the guidelines for the study of pain in awake animals established by the International Association for the Study of Pain [36] . Experiments were conducted in 453 adult male C57BL/6N mice (Nihon SLC, Shizuoka, Japan; http://www.jslc.co.jp/), aged 10-12 weeks, with a mean body weight of 27.5 6 0.82 g (6SD), and 20 adult male mice in which enhanced GFP (EGFP) expression was driven by the cytomegalovirus early enhancer b-actin (CAG) transgene (CAG-EGFP mice; Nihon SLC, Shizuoka, Japan), aged 6-8 weeks, with a mean body weight of 19.4 6 0.47 g (6 SD). The experimental protocol was approved by the Ethics Committee for Animal Experimentation of Fukui University.
The Contusion SCI Model
Each mouse was anesthetized before surgery with isoflurane (Forane; Abbot, Tokyo, Japan; http://www.abbott.co.jp/), and the spinal cord was exposed by laminectomy at the T9-T10 vertebral level using a surgical microscope (VANOX-S; Olympus Optical, Tokyo, Japan; http://www.olympus.co.jp). A contusion SCI was produced using the Infinite Horizon Impactor (Precision Systems and Instrumentation LLC, Fairfax, VA; http:// www.presysin.com/) with an impact force of 60 kilodynes (kdyn) [37] . In a sham SCI operation group, each mouse underwent a laminectomy only at the T9-T10 vertebral level, with no SCI performed.
Preparation of Bone Marrow-Derived Mesenchymal Stem Cells
BMSC were isolated and cultured from the bone marrow of the femur and tibia bones collected from young adult male C57BL/ 6N or CAG-EGFP transgenic mice. The prepared bone marrow cells were placed into dishes with Dulbecco's modified Eagle's medium (DMEM; GIBCO, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS; GIBCO; http://www.lifetechnologies.com/). Dissociated BMSC were isolated according to preferential adherence to tissue culture plastic as described in Supporting Information Methods. Before all experiments using BMSC transplants, flow cytometric analysis confirmed that these cells were phenotypically BMSC based on positive immunostaining for CD44, CD90, and CD29 and negative immunostaining for CD45 and CD11b (Supporting Information Fig. 1 ).
BMSC Transplantation
We divided animals into four groups according to the time of transplantation of BMSCs that were isolated from C57BL/6N mice. The BMSC transplantation was performed on days 1, 3, 7, and 14 post-SCI. The treatment group received 2.0 3 10 5 BMSC in 3 ll of DMEM, which were injected into the middle of the contusion site, identified as the middle point of the laminectomy area (identified by a hematoma at day 3) [38] . To maximize engraftment of all injected BMSC into the spinal cord, the needle was not disconnected from the spinal cord for 5 minutes after the injection. Control mice were injected with 3 ll of DMEM alone (i.e., no cells) at each time point post-SCI. Shamoperated mice were not injected with cells or with DMEM.
Assessment of Transplanted BMSC Survival
The relationship between the survival rates of transplanted BMSCs with the time after SCI that the BMSCs were transplanted was initially assessed. The transplantation for these survival studies were at 1, 3, 7, and 14 days post-injury. GFPpositive BMSC survival was examined at 15 
Bone Marrow-Chimeric Mice
We generated bone marrow-chimeric mice using highly purified, genetically marked bone marrow cells as reported previously [34, 39] , enabling us to limit our studies to hematopoietic lineages. Isolated unfractionated marrow cells (5.0 3 10 6 cells) from donor CAG-EGFP transgenic mice were injected intravenously into the tail vein of a recipient mouse that had been irradiated at 9.0 Gy for 30 minutes (4.5 Gy/15 minutes twice) after covering the head with a lead plate. Their successful engraftment and induction of chimerism was confirmed after 4 weeks by Dual-laser Fluorescence-Activated Cell Sorting (FACS) Calibur (BD Biosciences, San Jose, CA; http://www.bdbiosciences.com/) analysis of recipient peripheral blood to identify donor GFP 1 -bone marrow-derived cells. Bone marrow chimeric mice were used for SCI surgery at the age of 10-12 weeks.
Behavioral and Sensory Testing
The Basso Mouse Locomotor Scale (BMS) is a 0 to 9-point scale, which was developed to describe recovery of locomotor function in mice after thoracic spinal cord contusion or transection injury [40] . BMS scores were recorded at times indicated post-SCI for the left and right hind limbs, and averaged to obtain a single calculated value per mouse per test.
Mechanical allodynia and thermal sensitivity were recorded at times indicated post-SCI by two independent examiners blinded to the experimental conditions. Mechanical allodynia was assessed using the Dynamic Plantar Aesthesiometer (Ugo Basile, Comerio, Italy; http://www.ugobasile.com/) [41] . The withdrawal threshold (expressed in grams) was measured five times and the reported value represents the mean of these five evaluations. Thermal sensitivity of the plantar hindpaws was tested according to the method described previously [42] (Plantar Test Apparatus, Ugo Basile) (Supporting Information Methods). Latency (in seconds) to withdrawal from the heat source was recorded, together with any other behavior indicating attendance to the stimulus, including sniffing, licking, looking at the affected paw, or attacking the stimulus. High and low latencies were dropped for each paw, and the remaining six latencies were averaged for each mouse [43] .
We used the same technique to transplant 2.0 3 10
5
BMSCs in 3 ll DMEM versus 3 ll DMEM alone (as controls) at day 3 post-SCI for detailed analysis of biochemistry related to pain hypersensitivity. Previous reports indicate that allodynia is present in approximately 81% of experimental mouse models after SCI [44] and approximately 75% of experimental rat models after contusion SCI [45] . For this study, 142 mice underwent contusion SCI and were examined using sensory tests for the presence of allodynia and 111 (78.2%) of these were selected based on the presence of significant sensory differences when compared with the sham-operated group.
Immunohistochemistry
Perfused segments of the spinal cord obtained from separate animals were embedded in optimal cutting temperature compound (Sakura Finetek, Torrance, CA; http://www.sakura-finetek.com/) and cut on a cryostat for the preparation and analysis of axial sections (for assessment of dorsal horn and gray matter after SCI) or sagittal sections (for assessment of the distribution of transplanted BMSCs and blood-derived cells). All frozen sections were 20 lm thick and serially mounted on glass slides (Supporting Information Methods). All digitized images of immunopositivity were obtained using a fluorescence microscope (Olympus AX80; Olympus Optical) or a confocal laser scanning microscope (model TCS SP2; Leica Instruments, Nussloch, Germany; http://www.leica.com/).
Semi-Quantitative Analysis of Tissue Staining
For semiquantitative analysis of dorsal horn neuronal hyperexcitability, 10 axial sections randomly selected at a distance up to 2 mm rostral and caudal to the site of the lesion were immunostained with antibodies specific for putative markers, that is, for protein kinase C-c (PKC-c) or phosphocyclic AMP response element binding protein (p-CREB), both of which are upregulated in association with at-level allodynia after contusion SCI [21, 27] . For PKC-c staining in the superficial laminae I-III of spinal dorsal horn, the area and density of pixels within the threshold value representing immunoreactivity were calculated. The extent of immunopositivity for each antibody was calculated from the product of pixel density and image area, which was determined using the color image analyzer (MacSCOPE; Mitani, Fukui, Japan; http://mitani-visual.jp/). For p-CREB staining, the numbers of p-CREB-and neuronal nuclei (NeuN)-double-positive cells in the superficial laminae I-III of the spinal dorsal horn were counted, as reported previously [46] . The number of GFP-positive BMSCs, CD11b-and GFPpositive cells, CD11b-positive and GFP-negative cells, and p-38 MAPK and p-ERK1/2 colocalized with GFP positive cells were counted. For this analysis, three mid-sagittal sections through the injured portion of the spinal cord were randomly selected and 20 high magnification (4003) nonoverlapping digitized images were captured using a confocal microscope (TCS SP2) within a region that was 2 mm rostral and caudal to the site of lesion. Quantification of cells in each image was performed by MacSCOPE as described previously [47] .
We assessed BSCB function at days 4, 7, and 14 post-SCI, because we previously observed that the infiltration of bloodderived macrophages peaked between 1 and 2 weeks after SCI. BSCB was assessed as follows; 10 axial sections were randomly selected at a distance up to 2 mm rostral and caudal to the site of lesion and stained for albumin or immunolabeled for platelet-derived growth factor receptor a (PDGFR-a). Digitized images of the stained sections were collected and Mac-SCOPE was used to calculate the relative intensity of albuminand PDGFR-a-positive signal intensity in the gray matter. The mean pixel density of positivity was expressed as a percentage of that for the total fields analyzed (pixel area/total field) [48] .
Flow Cytometric Analysis
At day 14 post-SCI, the damaged area of the spinal cord (2.5 mm either side of the lesion) was surgically dissected for flow cytometry, as described previously [49] 
Immunoblot Analysis
Immediately after deep anesthesia, the damaged spinal cord (2.5 mm either side of the lesion) was removed at days 4 or 14 post-SCI and stored immediately at 280 C in liquid nitrogen. Western blotting was performed as described in Supporting Information Methods. Images for immunoblot analysis were captured on an Image Quant LAS 4000 mini chemiluminescence imaging analyzer (GE Healthcare Life Science, Piscataway, NJ; http://www3.gehealthcare.com/) and the band intensity was quantified using Image Quant TL software (GE Healthcare Life Science). The intensity of each band was expressed relative to that of b-actin. Kaleidoscope Prestained Standards (Bio-Rad Laboratories, Hercules, CA) were used as molecular weight controls.
Statistical Analysis
All values are expressed as mean 6 SD. Differences between groups were examined for statistical significance using oneway factorial analysis of variance. A p < 0.05 denoted the presence of significant difference with Tukey's posthoc analysis. The above tests were conducted using SPSS software version 11.0 (SPSS, Chicago, IL).
RESULTS
Relationship Between Survival Rate of Transplanted BMSCs and Time of Transplantation
There was a decrease in the presence of GFP-positive transplanted BMSCs with time after transplantation such that by 28 days post BMSC transplant very few viable BMSCs were observed. However, the number of surviving BMSCs that had been transplanted at 1 or 3 days after SCI were markedly greater than the number of surviving BMSCs that were transplanted at 7 or 14 days after SCI, with the greatest survived number seen when BMSCs were transplanted at 3 days (Supporting Information Fig. 2 ).
Early transplantation of BMSCs After SCI Increases Locomotor Function and Decreases Pain Hypersensitivity to Mechanical and Thermal Stimulation
The effects of BMSC transplants were examined at the acute, sub-acute and chronic stages after SCI (days 1, 3, 7 and 14). This was to examine whether effects of the transplants on pain hypersensitivity may be time dependent, and potentially related to inflammatory reactions.
After BMSC transplantation at 14 days post-SCI, there were no significant effects in behavioral or sensory test outcomes. In contrast, the mice that were treated with BMSCs at 3 days post-SCI showed the greatest improvement in their BMS locomotor scores compared with the control group, which was significantly increased by day 14 post-SCI and persisted up to week 6 after injury (Fig. 1A) . Furthermore, the most marked improvements in mechanical and thermal sensitivity scores were also seen in the 3 day BMSC-treated group (Fig. 1B, 1C ) (see also Supporting Information Fig. 3 ). Subsequent analyses were performed on 3 day BMSC-treated mice versus control or sham-operated mice.
BMSC Transplantation Reduced PKC-c-and p-CREB Protein Levels Spinal Cord Dorsal Horn Neurons
To examine whether BMSC transplantation reduces localized putative markers of hyperexcitability in neurons, we assessed immunopositivity for PKC-c and p-CREB colocalized with the neuronal marker, NeuN in the dorsal horn post-SCI. In the control group, SCI caused an increase in PKC-c-positivity in NeuN-labeled neurons in the dorsal horn of the spinal cord around the injury site. In contrast, BMSC transplantation significantly suppressed the observed expression of PKC-c in NeuN-labeled cells in these locations (Fig. 2A, 2B) . The number of cells positive for both p-CREB and NeuN in the dorsal horn post-SCI was also increased in the control group, (Fig. 2E, 2F ). Immunoblot analysis of extracted proteins from the lesion site following SCI confirmed that the protein levels of PKC-c and p-CREB were decreased in the BMSC transplantation group compared with the control group (Fig. 2C, 2D, 2G, 2H ).
BMSC Transplantation Decreased the Upregulation of p-p38 MAPK-or p-ERK1/2-in CD11b Positive Cells in the Spinal Cord Dorsal Horn
We mapped the presence of the MAPK family, that is, p-p38 MAPK, p-ERK1/2, and p-JNK in the spinal cord after SCI.
Although the observed levels of p-p38 MAPK, p-ERK1/2, and p-JNK were weak in the intact spinal cord (data not shown), marked increases in p-p38 MAPK, p-ERK1/2, and p-JNK were noted in all laminae within the spinal cord dorsal horn at day 14 post-SCI in the control group. The observed increase in expression of p-p38 was robust and tightly colocalized with cells that were positive for CD11b, but almost negligible with NeuN and glial fibrillary acidic protein (GFAP)-positive neurons and astrocytes, respectively. Similarly, p-ERK1/2 colocalized with CD11b positivity, and there was also some colocalization of p-ERK1/2 with GFAP-labeled cells, but very little colocalization with NeuN-positive cells. P-JNK positivity colocalized with some GFAP-positive cells, but was also seen, although weakly, with some NeuN and CD11b-positive cells (Supporting Information Fig. 4) . We evaluated the effects of BMSC transplantation on pp38 MAPK-and p-ERK1/2 levels in CD11b positive cells by examining tissue sections post-SCI following dual immunohistochemical labelling for these markers and by immunoblotting of extracted proteins. Axial sections were used for the evaluation of MAPK activities in the injured spinal dorsal horn, where a reduction in the number of dual-labeled cells, especially in the spinal dorsal horn, was seen in the mice that received BMSC transplants compared with the control group. In contrast, the levels of expression of p-p38 MAPK and p-ERK1/2 did not change in sham-operated group (Fig. 3A, 3B , 3E, 3F). In addition, protein levels of p-p38 MAPK and p-ERK1/2 were decreased in the BMSC transplantation group compared with the control group (Fig. 3C, 3D, 3G, 3H ).
BMSC Transplantation Inhibited the Recruitment of CD11b and GFP-Positive Hematogenous Cells to the Lesion after SCI
To determine whether BMSC transplantation affects the recruitment of bone marrow-derived cells into the injured spinal cord, the contusive SCI was reproduced in chimeric mice wherein the hematogenous cells were GFP labeled. Immunostaining of mid-sagittal sections of the spinal cord post-SCI revealed a transient increase in the numbers of CD11b positive cells that colocalized with GFP positive cells in the control group and BMSC-treated group, both of which peaked at 14 days after injury. However, the distribution of cells that were dual labeled for CD11b and GFP was localized more to the lesion site in the BMSC transplantation group (Fig. 4) . In contrast, CD11b positivity was weak and there was little evidence of migration of GFP-positive cells into the spinal cord in the sham-operated group. In addition, there were significantly fewer CD11b and GFP dual-labeled cells in the spinal cord at days 14 and 28 post-SCI in the BMSC transplanted group compared with the control group (Fig. 4D) . In contrast, the numbers of CD11b-positive and GFP-negative cells in the spinal cord tended to be higher in the BMSC transplanted group than in the control group, although insignificantly (Fig. 4E) .
BMSC Transplantation Suppressed the Activation of pp38 MAPK and p-ERK1/2 in Bone Marrow-derived Macrophages and Resident Microglia After SCI, and Prevented Recruitment of Hematogenous Macrophages into the Injured Spinal Cord
In control mice, SCI resulted in an observed increase in the presence of cells that were dually labeled with p-p38 MAPK and GFP-or p-ERK1/2 and GFP within the spinal cord dorsal horn. In contrast, BMSC transplantation not only appeared to prevent the recruitment of GFP-positive bone marrow-derived cells into the spinal cord dorsal column but it also appeared to decrease their coexpression of p-p38 MAPK and p-ERK1/2 (Supporting Information Fig. 5 ).
Flow cytometry confirmed the observed effects of BMSC transplantation in attenuating the infiltration of hematogenous macrophages and inhibiting the activation of those fewer cells that were recruited as well as the resident microglia. The number of CD11b and GFP dual-labeled cells was significantly lower in the BMSC transplantation group compared with the control group (Fig. 5A-5C ). In the subpopulation of cells that was GFP positive /CD11b positive /CD45 positive /Gr-1 negative (i.e., hematogenous macrophages), the number (percentages) of activated p-p38 MAPK and p-ERK1/2-positive cells were 2778 6 55 (97.6%) and 2792 6 45 (98.1%) in the control group, and 976 6 286 (65.6%) and 686 6 153 (46.1%), respectively, in the BMSC transplantation group; these represented significant differences (Fig. 5D-5G ). In the subpopulation of cells that were GFP negative /CD11b positive /CD45 positive /Gr-1 negative (i.e., resident microglia), the number (percentages) of activated p-p38 MAPK and p-ERK1/2-positive cells were 9101 6 267 (96.5%) and 7950 6 329 (84.3%) in the control group, and 1920 6 391 (58.2%) and 1023 6 478 (31.0%), respectively, in the BMSC transplantation group; these also represented significant differences (Fig. 5H-5K ).
The Effects of BMSC Transplantation on BSCB Function
The effects of BMSC transplantation on the BSCB were evaluated by examining the presence of albumin, which leaks into the parenchyma after central nerve system injury and PDGFRa, which localize on perivascular astrocytic endfeet [49] . After the initial injury, BMSC transplantation significantly reduced leakage of albumin into the injury site at day 7 post-SCI compared with the control group, while at day 14 post-SCI only minor leakage of albumin was identified in both groups (Fig.  6A, 6C ). Similarly, a significant reduction in PDGFR-a immunoreactivity at the lesion site was seen at day 7 post-SCI in the BMSC transplantation group compared with the control group, with a further reduction observed in both groups at day 14 ( Fig. 6B, 6D ).
BMSC Transplantation Moderated the Cytokine Profile at the Lesion Site After SCI
Finally, we measured protein levels of tumor necrosis factor a (TNF-a) and interleukin (IL)26 (as proinflammatory cytokines), matrix metallopeptidase 9 (MMP-9) (as a mediator of early 
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secondary vascular pathogenesis), chemotactic cytokine ligand (CCL) 2, CCL5, CXC chemokine (C-X-C motif) ligand 10 (CXCL10) (as macrophage recruiting factors), and granulocytemacrophage colony-stimulating factor (GM-CSF) (as a local microglial stimulating factor) at day 4 post-SCI (i.e., day 1 after transplantation) by immunoblot analysis. BMSC transplantation reduced the intensities of the bands for TNF-a, IL-6, MMP-9, CCL2, CCL5, and CXCL10, but increased that of GM-CSF, compared with the SCI control group (Fig. 7) .
DISCUSSION
Transplantation of BMSCs after SCI has been shown consistently to improve motor function following SCI [51, 52] ; however, the effect of BMSC transplants on neuropathic pain or pain hypersensitivity is less clear [9] [10] [11] [12] . Understanding the possible outcome and mechanisms of action of BMSC transplantations in terms of pain is an important issue, especially as BMSCs are being considered for clinical treatments of SCI. This study demonstrated significant improvements in motor function as well as mechanical allodynia and thermal hyperalgesia in a contusion model of thoracic SCI as a result of BMSC transplantation. The findings were most marked in SCI animals that were transplanted with BMSCs at 3 days after injury, with no significant improvement seen when animals were transplanted at 14 days post-SCI. Previously, we demonstrated that the greatest survival of transplanted BMSCs was also achieved when these cells were transplanted at day 3 post-SCI, compared with transplantation at days 1, 7, and 14 post-SCI; furthermore, we and others found that day 3 post-SCI is the time point when the numbers of major inflammatory cells are still increasing in the injury site [39, 53] . Based on these previous finding, as well as the present results, we Watanabe, Uchida, Nakajima et al. 1909 www.StemCells.com V C 2015 The Authors STEM CELLS published by Wiley Periodicals, Inc. on behalf of AlphaMed Press suggest that transplantation of BMSCs in the acute as opposed to subacute phase after SCI will have beneficial effects on post-SCI chronic neuropathic pain, at least in the short-term, which supports their early use in clinical treatments. Further research into methods designed to enhance the survival of transplanted BMSCs is warranted. We have demonstrated previously that blocking IL-6 signaling enhances BMSC survival and immunomodulatory and neuroprotective outcomes following BMSC transplantation [38] . Such a strategy may also prove beneficial to improve the effects of BMSC transplantation on neuropathic pain. In addition, a better understanding of the mechanisms of action of BMSCs in suppressing pain after SCI is essential to their successful therapeutic application. Activation of the MAPK signaling pathway in dorsal horn neurons and glial cells contributes to the development and maintenance of neuropathic pain, which promotes long-term potentiation and central sensitization. MAPK signaling cascades are indicated through phosphorylation and hence activation of ERK1/2, JNK, and p38 MAPK; this in turn can lead to phosphorylation and activation of the transcription factor, CREB [19] . Activated CREB regulates the NR1 subunit on the NMDA channel [19] and is upregulated in spinothalamic tract cells in association with the development of neuropathic pain [54] . Phosphorylated PKC-c is another important intracellular signaling protein found in a specific subset of excitatory interneurons in the inner region of lamina II, which receive input from myelinated, non-noxious afferents [55] . PKC-c has similarly been associated with neuropathic pain behavior [56] . The present results indicated that early BMSC transplantation suppressed the activation of p38 MAPK and ERK1/2 in microglia and macrophages as well as that of CREB and PKC-c in dorsal horn neurons in and around the lesion. This demonstrates that early BMSC transplants after SCI suppressed several pain signaling pathways and raises the question as to how BMSCs might bring about these effects. Several studies using animal models of neural damage showed that MSC, including BMSCs, inhibit microglial activation and inflammatory responses [9, 57, 58] . In vitro experiments have demonstrated that MSC reduce the proinflammatory potential of dendritic cells and natural killer cells by inhibiting the production of inflammatory factors, including TNF-a and interferon c (IFN-c) [59] and they also inhibit the activation of microglial cells [23, 60] . We have reported previously that BMSCs enhance neuroregeneration through overexpression of neurotrophic factors as well as through modulation of immune responses following SCI from an inflammatory (M1) to an alternatively activated (M2) macrophage phenotype. This was associated with downregulation of T helper 1 (Th1)-type cytokines TNF-a and IFN-c and increased levels of Th2-type cytokines IL-4 and IL-13 at the site of injury [39, 52] . Hence, this and previous work has provided compelling evidence that early BMSC transplants after SCI suppress pain signaling pathways and pain hypersensitivity through their anti-inflammatory and immunomodulatory activity.
The pathogenesis of neuropathic pain and central sensitization after peripheral nerve injury seems to involve spinal cord microglia as well as macrophages derived from hematogenous monocytes [34. 35] . We used GFP-labeled bone marrow chimeric mice in this study for a better understanding of the relative roles of these different cell types in SCI. The prevalence of activated resident microglia and infiltrating macrophages increased after SCI especially at day 14 when the most severe pain hypersensitivity was noted in the control group (Figs. 4 and 5) . BMSC transplantation decreased p-p38 MAPK and p-ERK1/2 positivity both in the resident microglia (GFP-negative cells) and hematogenous macrophages (GFPpositive cells), indicating that BMSCs suppressed the activation of both cell types (Fig. 5) . Furthermore, BMSC transplantation significantly reduced the recruitment of CD11b-and GFP-dual-labeled hematogenous macrophages at days 14 and 28 to the injury site (Fig, 4D) . The decrease in hematogenous macrophage infiltration into the injured spinal cord after BMSC transplantation was associated with modifications in the secreted profile of inflammatory cytokines and chemokines known to increase endothelial permeability and attract Figure 7 . Bone marrow-derived mesenchymal stem cell (BMSC) transplantation decreased protein levels of inflammatory cytokines and macrophage recruiting chemokines, while increasing that of granulocyte-macrophage colony-stimulating factor (GM-CSF). Each graph shows the relative band intensity of each protein normalized to that of b-actin. Western blotting showed significantly lower protein levels of TNF-a and IL-6 (inflammatory cytokines), MMP-9 (a mediator of early secondary vascular pathogenesis), and CCL2, CCL5, and CCXL10 (all macrophage recruiting factors), and significantly higher protein levels of GM-CSF (a microglial stimulating factor) in the BMSC transplanted group compared with the control group at day 4 post-SCI (n 5 3 each; *, p < 0.05). Data shown are means 6 SD. (A-C): One-way factorial analysis of variance. Abbreviations: BMSC, bone marrow-derived mesenchymal stem cells; CCL, chemotactic cytokine ligand; CCXL10, chemokine (C-X-C motif) ligand 10; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL-6, interleukin 6; MMP-9, matrix metallopeptidase 9; SCI, spinal cord injury; TNF-a, tumor necrosis factor a.
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Transplanted MSC Reduce Hypersensitivity After SCI V C 2015 The Authors STEM CELLS published by Wiley Periodicals, Inc. on behalf of AlphaMed Press STEM CELLS inflammatory cells to wound sites, that is, TNF-a, IL-6, MMP-9, CCL2, CCL5, and CXCL10 [35, [61] [62] [63] , as well as direct evidence of a restored BSCB, as shown through decreased cavitation in the lesion site, reduced staining for albumin, and evidence of tight junctions in the astrocytic endfeet and endothelial cells following PDGFR-a immunolocalization and electron microscopy at day 7 after SCI (Fig 6) [49, 64] . Of these changes, it is noteworthy that CCL2, a member of the chemokines family that has been recently identified as a possible key integrator of neuropathic pain in peripheral nerve injury and SCI [35] was downregulated following BMSC transplantation in our study. In contrast to the recruitment of hematogenous macrophages after SCI, proliferation of resident microglia is mainly regulated by colony-stimulating factors [65] . GM-CSF also facilitates axonal regeneration and functional recovery after SCI [31] . The local increase in GM-CSF at the injury level observed in our study could have stimulated the proliferation of microglia, which tended to increase the proportion of CD11b-positive and GFP-negative activated spinal cord microglia at the lesion site, although insignificantly (Fig. 4E ).
CONCLUSION
In this study, we have demonstrated that early BMSC transplants not only decreased the activation of MAPK signaling in injured spinal cord but also altered the localized presence of inflammatory mediators, which will have contributed to a decrease BSCB disruption and reduction in the recruitment of harmful blood-borne macrophages. The net effect of these changes is likely to play a major role in reducing pain hypersensitivity in the BMSC treated SCI animals.
